Search Within

Shanu Modi

Formats
  1. Meeting Abstract (151)
  2. Journal Article (101)
  3. Review (12)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (269)
  2. Department of Medicine (269)
  3. Solid Tumor Oncology Division (269)
  4. Survivorship Research (114)
  5. GSK Faculty (108)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (91)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (51)
  4. Sujata Patil (44)
  5. Chau Dang (42)
  6. Komal Jhaveri (35)

More People

Years
  1. 2025 (9)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (68)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (19)
  6. Nature Publishing Group (13)

More Publishers

Results (269)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
    Journal Article

    Jhaveri, K.; Miller, K.; Rosen, L.; Schneider, B.; Chap, L.; Hannah, A.; Zhong, Z.; Ma, W.; Hudis, C.; Modi, S.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
    Journal Article

    Gupta, M.; LoRusso, P. M.; Wang, B.; Yi, J. H.; Burris, H. A.; Beeram, M.; Modi, S.; Chu, Y. W.; Agresta, S.; Klencke, B.; more...
    Journal of Clinical Pharmacology (2012)

    Fulltext@MSK | Save
  • Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
    Journal Article

    Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G.
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2012)

    Fulltext@MSK | Save
  • Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer
    Meeting Abstract

    Modi, S.; Saura, C.; Henderson, C. A.; Lin, N. U.; Mahtani, R. L.; Goddard, J.; Rodenas, E.; O'Shaughnessy, J.; Baselga, J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Beyond HER2 and hormonal agents: The heat shock protein 90 inhibitor ganetespib as a potential new breast cancer therapy
    Meeting Abstract

    Friedland, J. C.; Sang, J.; Modi, S.; Bradley, R.; Ei-Hariry, I.; Wada, Y.; Proia, D. A.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Pharmacokinetics (PK) of trastuzumab emtansine and paclitaxel or docetaxel in patients with HER2-positive MBC previously treated with a trastuzumab-containing regimen
    Meeting Abstract

    Lu, D.; Modi, S.; Elias, A. D.; Agarwal, P.; Yi, J. H.; Guardino, A. E.; Althaus, B. L.; Girish, S.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save